Clinical Trials
54 trialsA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Nanjing Leads Biolabs Co.,Ltd
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors
HC Biopharma Inc.
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
HC Biopharma Inc.
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
MICA
Cullinan Therapeutics Inc.
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
A Study of WJ05129 in Advanced Malignant Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
A Study of TXN10128 in Subjects With Solid Tumors
Txinno Bioscience Inc.
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Astellas Pharma Inc
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
AO-176 in Multiple Solid Tumor Malignancies
Arch Oncology
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
Athenex, Inc.
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Athenex, Inc.
HLX07Ib/II
Shanghai Henlius Biotech
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Jiangsu HengRui Medicine Co., Ltd.
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
Capivasertib China PK Study
AstraZeneca
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Athenex, Inc.
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
Eli Lilly and Company
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Athenex, Inc.
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Athenex, Inc.
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Huabo Biopharm Co., Ltd.
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Novartis
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Daiichi Sankyo
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
AstraZeneca
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
AstraZeneca
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Study Evaluating Safety And Tolerability, Solid Tumor
Puma Biotechnology, Inc.
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
AbbVie
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
AbbVie
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Sanofi
Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
Debiopharm International SA